logo
OptimizeRx Corporation (NASDAQ:OPRX) is favoured by institutional owners who hold 59% of the company

OptimizeRx Corporation (NASDAQ:OPRX) is favoured by institutional owners who hold 59% of the company

Yahoo30-03-2025
Institutions' substantial holdings in OptimizeRx implies that they have significant influence over the company's share price
A total of 11 investors have a majority stake in the company with 52% ownership
Insiders have bought recently
This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.
A look at the shareholders of OptimizeRx Corporation (NASDAQ:OPRX) can tell us which group is most powerful. And the group that holds the biggest piece of the pie are institutions with 59% ownership. Put another way, the group faces the maximum upside potential (or downside risk).
Since institutional have access to huge amounts of capital, their market moves tend to receive a lot of scrutiny by retail or individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait.
In the chart below, we zoom in on the different ownership groups of OptimizeRx.
See our latest analysis for OptimizeRx
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
As you can see, institutional investors have a fair amount of stake in OptimizeRx. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of OptimizeRx, (below). Of course, keep in mind that there are other factors to consider, too.
Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. It would appear that 8.2% of OptimizeRx shares are controlled by hedge funds. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. Looking at our data, we can see that the largest shareholder is Whetstone Capital Advisors, LLC with 8.2% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 7.5% and 7.2%, of the shares outstanding, respectively.
A closer look at our ownership figures suggests that the top 11 shareholders have a combined ownership of 52% implying that no single shareholder has a majority.
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
Our information suggests that insiders maintain a significant holding in OptimizeRx Corporation. Insiders have a US$23m stake in this US$160m business. We would say this shows alignment with shareholders, but it is worth noting that the company is still quite small; some insiders may have founded the business. You can click here to see if those insiders have been buying or selling.
With a 18% ownership, the general public, mostly comprising of individual investors, have some degree of sway over OptimizeRx. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.
It's always worth thinking about the different groups who own shares in a company. But to understand OptimizeRx better, we need to consider many other factors. To that end, you should learn about the 2 warning signs we've spotted with OptimizeRx (including 1 which is a bit unpleasant) .
But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Can OPRX's Patient Engagement Tools Win Amid Fierce Competition?
Can OPRX's Patient Engagement Tools Win Amid Fierce Competition?

Yahoo

time6 days ago

  • Yahoo

Can OPRX's Patient Engagement Tools Win Amid Fierce Competition?

OptimizeRx OPRX delivered an encouraging first-quarter 2025, with revenues rising 11% year over year to $21.9 million and adjusted EBITDA reaching $1.5 million — a significant year-over-year turnaround. Despite its seasonally weakest quarter, OPRX is seeing momentum in its core platform, anchored by DAAP and advanced micro-neighborhood targeting. The company's strength lies in its broad reach across point-of-care networks and its ability to integrate direct-to-consumer (DTC) and HCP-facing campaigns. CEO Steve Silvestro emphasized that OPRX is being increasingly viewed as a strategic commercialization partner, especially as pharma spending gets more focused and selective. Their platform's ROI — claimed at over 10:1 — and a 25% script lift in six months underscore its value proposition in a tightening market. Also, more than 80% of its 2025 revenues are already contracted, and the company has begun shifting toward a subscription-based model, with early traction in data-as-a-service offerings. This could bring margin stability and predictability, which are key for long-term value creation. Though gross margin dipped slightly due to a higher mix of managed services, the company is confident about its ability sustain margins in the 60% range while expanding high-margin data solutions. OptimizeRx also addressed concerns about regulatory pressures and pharma budget volatility, stating it hasn't seen meaningful headwinds yet. Rather, there's greater client focus on cost-effective digital solutions, which could be a tailwind for OPRX. In a fiercely competitive digital health space where giants like Veeva are evolving rapidly, OPRX's integration of scalable omnichannel tools and data-driven insights may provide it with a durable edge if it continues to execute with discipline and agility. The challenge lies in scaling subscriptions while maintaining innovation to avoid margin pressures and defend its niche in a shifting digital engagement landscape. Tools From Peers Omnicell OMCL is reinforcing its digital health strategy through the Intelligence-Enabled Pharmacy vision. The company is scaling its OmniSphere platform — a cloud-based, AI-powered solution that offers predictive analytics and real-time medication inventory management. Despite near-term macroeconomic challenges and a pause in large-scale capex projects, Omnicell remains committed to automating and digitally transforming medication management workflows across hospitals and health systems. OMCL's Advanced Services suite further integrates automation, analytics, and remote pharmacy services, aimed at optimizing clinical and financial outcomes for healthcare providers. These innovations position Omnicell as a strategic enabler of smart, data-driven pharmacy operations. Teladoc Health TDOC is doubling down on digital mental health with its BetterHelp platform and recent acquisition of UpLift, an in-network virtual mental health provider. This move enables Teladoc to offer covered-benefits therapy options to users, improving conversion rates and reducing out-of-pocket costs. UpLift's network of more than 1,500 licensed professionals complements BetterHelp's reach of 35,000 therapists, supporting therapy, psychiatry and medication management. Teladoc is also investing in AI-enabled clinical documentation tools and its Prism care delivery platform, which enhances integration across the virtual care ecosystem. These steps underline its ambition to deliver scalable, tech-driven behavioral and chronic care solutions globally. OPRX's Price Performance, Valuation and Estimates Shares of OptimizeRx have surged 187.9% year to date compared with the industry's growth of 18%. Image Source: Zacks Investment Research OPRX's forward 12-month P/S of 2.33X is lower than the industry's average of 8.86X, and also lower than its five-year median of 3.57X. However, it carries a Value Scoreof F. Image Source: Zacks Investment Research The Zacks Consensus Estimate for OPRX's 2025 earnings per share suggests a 63.6% improvement from the 2024 level. Image Source: Zacks Investment Research OptimizeRx stock currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Omnicell, Inc. (OMCL) : Free Stock Analysis Report OptimizeRx Corp. (OPRX) : Free Stock Analysis Report Teladoc Health, Inc. (TDOC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research

Can OptimizeRx Maintain Profit Growth Amid Evolving Pharma Spend?
Can OptimizeRx Maintain Profit Growth Amid Evolving Pharma Spend?

Yahoo

time04-07-2025

  • Yahoo

Can OptimizeRx Maintain Profit Growth Amid Evolving Pharma Spend?

OptimizeRx OPRX kicked off 2025 with strong momentum, delivering 11% year-over-year revenue growth to $21.9 million and turning in $1.5 million in adjusted EBITDA, its strongest first-quarter performance to date. The digital health company's cost discipline and strategic client engagement efforts translated into a narrower net loss and stronger operating cash flow of $3.9 million, supporting a cash balance of $16.6 million. The company raised full-year revenue guidance to $101-$106 million and expects adjusted EBITDA between $13-$15 million, citing a strong pipeline. The company's existing contracts are likely to generate more than 80% of the revenue guidance. A notable strategic shift is the move toward a subscription-based revenue model, with early adoption already exceeding 5% of projected revenues. This shift, coupled with a broad and scalable tech platform, is designed to smooth revenue flows, enhance margins and deepen client stickiness. However, gross margins came in slightly lower at 60.9% versus 62% last year, reflecting a higher mix of lower-margin DTC managed services. While management aims to lift margins over time, the current mix suggests some near-term pressure depending on solution uptake. Critically, pharma clients are increasingly focused on efficiency and ROI in their marketing budgets amid regulatory shifts and evolving channel strategies. OptimizeRx's omnichannel platform — leveraging point-of-care integration and real-world patient targeting — appears well aligned with these priorities. Early results show a script lift of 25% and a 10:1 ROI, reinforcing its value proposition. OptimizeRx is navigating macro uncertainty with agility, benefiting from a growing base of committed revenues, cost efficiencies and a pivot to subscriptions. Continued execution in monetizing data and deepening customer relationships will be key to sustaining profit growth as pharma spending recalibrates in an increasingly digital landscape. Veeva Systems VEEV reported strong first-quarter fiscal 2026 results with $759 million in revenues, up 16.7% year over year, driven by robust adoption of Vault CRM and Crossix. Management remains optimistic despite macro uncertainty, emphasizing resilient subscription revenues and a growing product pipeline. Crossix, which offers short-cycle ROI on pharma marketing, is seeing over 30% year-over-year growth and is viewed as relatively insulated from budget pressure. The company is also advancing Veeva AI to deepen customer value and aims to increase commercial productivity, positioning itself as a critical partner as pharma clients prioritize efficiency and measurable outcomes. Health Catalyst HCAT delivered $79.4 million in first-quarter of 2025 revenue, up 6.3% year-over-year, with its tech platform Ignite driving 10% growth. Amid shifting pharma and healthcare funding, HCAT's modular, lower-cost Ignite platform enables faster ROI and shorter sales cycles, making it attractive in constrained budget environments. The company sees strong client uptake, particularly from existing app users, and expects 40 net new Ignite clients in 2025. While some booking delays occurred due to Medicaid and research funding uncertainty, HCAT believes the long-term value and pricing flexibility of Ignite will sustain growth. Full-year guidance was maintained, reflecting confidence in pipeline conversion. Shares of OptimizeRx have surged 176.4% year to date compared with the industry's growth of 15%. Image Source: Zacks Investment Research OPRX's forward 12-month P/S of 2.25X is lower than the industry's average of 8.67X, and also lower than its five-year median of 3.63X. However, it carries a Value Score of F. Image Source: Zacks Investment Research The Zacks Consensus Estimate for OPRX's 2025 earnings per share suggests a 63.6% improvement from 2024. Image Source: Zacks Investment Research OptimizeRx stock currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report OptimizeRx Corp. (OPRX) : Free Stock Analysis Report Veeva Systems Inc. (VEEV) : Free Stock Analysis Report Health Catalyst, Inc. (HCAT) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Investors in OptimizeRx (NASDAQ:OPRX) have unfortunately lost 55% over the last three years
Investors in OptimizeRx (NASDAQ:OPRX) have unfortunately lost 55% over the last three years

Yahoo

time04-07-2025

  • Yahoo

Investors in OptimizeRx (NASDAQ:OPRX) have unfortunately lost 55% over the last three years

It is doubtless a positive to see that the OptimizeRx Corporation (NASDAQ:OPRX) share price has gained some 73% in the last three months. But that is small recompense for the exasperating returns over three years. Indeed, the share price is down a tragic 55% in the last three years. Some might say the recent bounce is to be expected after such a bad drop. While many would remain nervous, there could be further gains if the business can put its best foot forward. It's worthwhile assessing if the company's economics have been moving in lockstep with these underwhelming shareholder returns, or if there is some disparity between the two. So let's do just that. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Because OptimizeRx made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size. Over three years, OptimizeRx grew revenue at 16% per year. That's a fairly respectable growth rate. So some shareholders would be frustrated with the compound loss of 16% per year. The market must have had really high expectations to be disappointed with this progress. So this is one stock that might be worth investigating further, or even adding to your watchlist. The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail). We consider it positive that insiders have made significant purchases in the last year. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. So we recommend checking out this free report showing consensus forecasts It's good to see that OptimizeRx has rewarded shareholders with a total shareholder return of 34% in the last twelve months. Notably the five-year annualised TSR loss of 1.3% per year compares very unfavourably with the recent share price performance. The long term loss makes us cautious, but the short term TSR gain certainly hints at a brighter future. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Take risks, for example - OptimizeRx has 1 warning sign we think you should be aware of. If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: most of them are flying under the radar). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store